Just reported
From Edwards Lifesciences's results release of 2026年11月4日; its quarterly report has since been filed.
Actual
US$1.72B
+10% y/y
-1.5% q/q
Guided
US$1.67B
midpoint
Actual
US$0.53
+6.0% y/y
+26% q/q
Guided
—
No guide given
Actual
US$299.1M
-2.6% y/y
-42% q/q
Guided
—
No guide given
Q4 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
各项收入占比是对nine months ended September 30, 2026的估算,并非来自已提交报告的数字。
SAPIEN
A family of tissue valves delivered through a catheter to replace a diseased aortic valve; some systems are also used for pulmonary valve replacement.
PASCAL
A catheter-delivered device that helps bring together the leaflets of a leaking mitral or tricuspid valve.
EVOQUE
A tissue valve delivered through a catheter to replace a leaking tricuspid valve.
SAPIEN M3
A tissue valve delivered through a catheter to replace a diseased mitral valve.
INSPIRIS RESILIA, KONECT RESILIA, and MITRIS RESILIA
Surgical tissue valve products for aortic and mitral valve replacement; KONECT is a tissue valve conduit used in complex combined procedures.
Edwards makes devices that replace or repair damaged heart valves. Some are delivered through a catheter, a thin tube passed through a blood vessel, while others are implanted during open-heart surgery. Hospitals and heart specialists use these devices to treat diseases affecting the aortic, mitral, and tricuspid valves.
基于 Edwards Lifesciences Corporation 自己向美国证券交易委员会(SEC)提交的申报文件。数字如实呈报,每股历史已重述到今天的股数口径。 这是对一门生意的描述——不是投资建议,也不是买卖任何证券的推荐。
The themes Edwards Lifesciences is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
US$107.19+1.3%11月13日 收盘
数据截至2026年9月30日,来自2026年11月4日提交的10-Q
Edwards Lifesciences sells catheter-delivered heart valves and repair devices, plus surgical replacement valves, to hospitals treating people with heart valve disease.
公司指引:2026 财年第 4 季度营收 US$1.7B 至 US$1.8B — 同比增长 8.9%
Grade A+
价格下方的色带显示每个日期的评级,仅依据当时已公开的文件计算。
显示 Edwards Lifesciences Corporation 评级历史 41 个季度中的 2 个。 其余 39 个可回溯到 2016年10月。